News Boehringer eyes H2 drug launches after strong H1 growth Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025,
News Boehringer drug scores in another pulmonary fibrosis trial Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.
News Trial sets up filings for Boehringer IPF drug nerandomilast With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O
Digital Axtria Ignite 2025: Madhavi Ramakrishna on leadership, cultu... GSK's Madhavi Ramakrishna was the recipient of one of the annual Axtria Ignite Leadership Awards presented at the invite-only summit.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
